Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Personalized Medicine Année : 2024

Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network

Matthieu Jabbour
  • Fonction : Auteur
Laurent Kodjikian
  • Fonction : Auteur
Alexandre Bourdin
  • Fonction : Auteur
Yasmine Serrar
  • Fonction : Auteur
Michel Weber
  • Fonction : Auteur
Helene Masse
  • Fonction : Auteur
Driss Mazhar
  • Fonction : Auteur
Sara Perez-Roustit
  • Fonction : Auteur
Christophe Chiquet
  • Fonction : Auteur
Bahram Bodaghi
  • Fonction : Auteur
Sara Touhami
  • Fonction : Auteur

Résumé

PURPOSE: To evaluate the safety and efficacy of the fluocinolone acetonide implant (FAi, Iluvien(®) Horus pharma, Nice, France) in non-infectious uveitic macular edema (UME) and to approach the predictive factors of treatment response. METHODS: This retrospective, multicenter real-life study included patients with chronic non-infectious UME who received intravitreal FAi after at least two dexamethasone implants (DEXi). RESULTS: Twenty-six eyes from 22 patients (73.1% of females) were included. The mean age was 60.4 ± 16 years. The mean follow-up was 11.4 ± 2 months. The mean baseline best-corrected visual acuity (BCVA) was 0.43 ± 0.36 LogMAR, improving significantly after 1, 3, 6 and 12 months (all p < 0.05 vs. baseline). The mean baseline central macular thickness (CMT) was 429 ± 110 μm, improving significantly after 1, 3, 6 and 12 months (all p < 0.05 vs. baseline). Five eyes (19.2%) developed ocular hypertension during the follow-up, requiring initiation or strengthening of intraocular pressure lowering medication. The majority of eyes (77%) did not require any rescue DEXi during the available 12-month follow-up. The resolution of UME after DEXi seemed to predict the anatomical response after FAi. The baseline presence of a disorganization of the inner retinal layers (DRIL) and hyperreflective foci (HRF) were both associated with a higher likelihood of requiring rescue DEXi injections. CONCLUSION: FAi implantation led to a significant BCVA and CMT improvement with a good safety profile over the 12-month follow-up. Predictive factors of treatment outcomes seem to include the anatomical response to DEXi and the presence of DRIL and HRF at baseline.
Fichier principal
Vignette du fichier
BPH_JPersMed_2024_Jabbour.pdf (1.4 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04569166 , version 1 (06-05-2024)

Licence

Paternité

Identifiants

Citer

Matthieu Jabbour, Laurent Kodjikian, Alexandre Bourdin, Marie-Benedicte Rougier, Yasmine Serrar, et al.. Efficacity and Safety of the Fluocinolone Acetonide Implant in Uveitic Macular Edema: A Real-Life Study from the French Uveitis Network. Journal of Personalized Medicine, 2024, 14 (3), ⟨10.3390/jpm14030245⟩. ⟨hal-04569166⟩

Collections

U1219
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More